Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526309 | 0.88 | KDM1A (0.46) | ALDH1A1KMT2AKDM1AOPRM1BDKRB1 | |
| SCHEMBL1018956 | 0.85 | SLC6A4 (0.46) | ALDH1A1KMT2AKDM1AOPRM1BDKRB1 | |
| SCHEMBL626449 | 0.85 | KDM1A (0.43) | ALDH1A1KMT2AKDM1AOPRM1BDKRB1 | |
| SCHEMBL1020648 | 0.83 | SLC6A4 (0.49) | ALDH1A1KMT2AKDM1ABDKRB1SLC6A4 | |
| SCHEMBL12369418 | 0.83 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL10253721 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KMT2AKDM1AOPRM1BDKRB1 | |
| Bromide SCHEMBL2270664 | 0.81 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL625294 | 0.81 | ICMT (0.44) | ALDH1A1KMT2AKDM1AOPRM1BDKRB1 | |
| SCHEMBL5726355 | 0.81 | KMT2A (0.40) | KMT2AOPRM1CYP2D6SLC6A4SLC6A3 | |
| SCHEMBL4442862 | 0.81 | KMT2A (0.40) | KMT2AOPRM1SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| CN-114085212-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-05-02 | — | — | CN | disclosed |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | ALDH1A1 2990/4885KMT2A 1301/4885KDM1A 716/4885 |
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | ALDH1A1 825/4885KMT2A 878/4885KDM1A 787/4885 |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CUL4B, CUL4A, UBQLN1 | ALDH1A1 825/4885KMT2A 878/4885KDM1A 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.